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Cancer Therapy: Preclinical
Species D Adenoviruses as Oncolytics against B-cell Cancers
Christopher Y. Chen1, Julien S. Senac2, Eric A. Weaver1, Shannon M. May1, Diane F. Jelinek3,4,
Philip Greipp4,5, Thomas Witzig4,5, and Michael A. Barry1,3,6
Abstract
Purpose: Oncolytic viruses are self-amplifying anticancer agents that make use of the natural ability of
viruses to kill cells. Adenovirus serotype 5 (Ad5) has been extensively tested against solid cancers, but less so
against B-cell cancers because these cells do not generally express the coxsackie and adenoviral receptor
(CAR). To determine whether other adenoviruses might have better potency, we "mined" the adenovirus
virome of 55 serotypes for viruses that could kill B-cell cancers.
Experimental Design: Fifteen adenoviruses selected to represent Ad species B, C, D, E, and F were tested
in vitro against cell lines and primary patient B-cell cancers for their ability to infect, replicate in, and kill
these cells. Select viruses were also tested against B-cell cancer xenografts in immunodeficient mice.
Results: Species D adenoviruses mediated most robust killing against a range of B-cell cancer cell lines,
against primary patient marginal zone lymphoma cells, and against primary patient CD138þ myeloma
cells in vitro. When injected into xenografts in vivo, single treatment with select species D viruses Ad26 and
Ad45 delayed lymphoma growth.
Conclusions: Relatively unstudied species D adenoviruses have a unique ability to infect and replicate in
B-cell cancers as compared with other adenovirus species. These data suggest these viruses have unique
biology in B cells and support translation of novel species D adenoviruses as oncolytics against B-cell
cancers. Clin Cancer Res; 17(21); 6712–22. 2011 AACR.
Introduction
B-cell malignancies can present as leukemias, myelomas,
and lymphomas. In the United States, there are more than
300,000 patients afflicted by these diseases for which
chemotherapy, radiation therapy, and stem cell transplan-
tation are themain treatments (1, 2). The spectrum of B-cell
cancers are thought to arise at different stages of the
ontogeny of normal B cells. For example, chronic lympho-
cytic leukemia (CLL) and small lymphocytic lymphoma
(SLL) may arise from intermediate andmature B cells; non-
Hodgkin’s lymphomas are thought to be generated from
mature immunoblasts; and myeloma is thought to arise
from differentiated plasma cells. Although therapies have
improved survival in many of these cancers, 5-year relative
survival is still only 60% for lymphomas, 50% for leuke-
mias, and 35% for myeloma. Therefore, complementary
therapies are needed to address those cancers that resist
current treatments.
Recent work has explored the use of viruses as cancer
therapies (reviewed in ref. 3). Certain viruses have cancer
killing or "oncolytic" capacity based on their intrinsic
ability to kill cells. These oncolytic viruses have appeal
because they are "self-amplifying" drugs, because each
infected and killed cancer cell can produce thousands of
progeny virions that can kill other cancer cells.
Adenoviruses (Ad) are nonenveloped DNA viruses that
are among those being tested as oncolytic agents (3, 4).
There are currently 55 serotypes of Ad that infect humans
and these serotypes distribute into 7 species (A–G). The
vast majority of oncolytic testing has been focused on 1
virus, Ad serotype 5 (Ad5) from species C. Ad5 has been
extensively tested for killing solid epithelial tumors in part
due to its ability to infect these cells via the coxsackie and
adenovirus receptor (CAR; reviewed in ref. 4). Although
Ad5 can be quite potent particularly against epithelial solid
tumors, 27% to 100% of humans are already immune to
this virus. Therefore, its utility may be restricted as an
oncolytic treatment for many patients.
Ad5 is markedly less potent against cells that do not
express CAR including most of the cells of the hematologic
system (5, 6). For this reason, Ad5 has not been applied
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extensively as an oncolytic against hematologic cancers.
This ineffectiveness is curious, particularly in light of the
fact that Ad5 and other Ad serotypes are frequently isolated
from human lymphoid tissues and peripheral blood
(reviewed in ref. 7). For example, species B, C, and E
Ads have been isolated or detected in human adenoids,
tonsils, and peripheral blood mononuclear cells (PBMC).
Consistent with this, species B viruses like Ad35 that bind
CD46 are substantially better at infecting cells of hemato-
logic origin (5, 6). Therefore, it is possible that other
adenoviral serotypes may be better than Ad5 as oncolytics
against hematologic malignancies.
Given there are 54 other serotypes of adenoviruses in 7
biologically diverse species, we recently screened low se-
roprevalence Ads from species B, C, D, and F for oncolytic
activity against the B-cell cancer myeloma (8). In this work,
we found that 2 species D viruses, Ad26 and 48, were more
potent than all other viruses including species C Ad5. This
was notable, because species D viruses make up 32 of the
55 known human Ads. Despite their abundance, this large
and diverse group of viruses is also the least studied for
basic virus biology and as oncolytics.
Given this and their high activity against B-cell–derived
myeloma cancers, we hypothesized that species D adeno-
viruses might have particular efficacy against B-cell cancers,
and that viral oncolysis might vary with the maturation
state of the B-cell cancer cells. To test these hypotheses, 7
species D adenoviruses were compared with 6 viruses from
species B, C, and E for their ability to kill B-cell cancers that
arose from various stages of B-cell ontogeny including CLL,
different stages of B-cell lymphoma, and myeloma.
Materials and Methods
Cell lines
The mouse myeloma cell line 5TGM1 and human
Burkitt’s lymphoma line Raji were generously provided
by Dr. Stephen Russell (Mayo Clinic). CHO-CD46 expres-
sing cells were generously provided by Dr. Kah Whye Peng
(Mayo Clinic). Human lymphoma RL and Hep3B human
hepatocarcinoma cells were obtained from American Type
Culture Collection (ATCC). Cells weremaintained in RPMI
1640 supplemented with 10% FBS (HyClone). The human
cancer cell linesMec-1 andMec-2 grew spontaneously from
a patient with B-CLL (9). Mec-1 and 2 cells were main-
tained in Iscove’s modified Dulbecco’s medium (IMDM)þ
Glutamax supplemented with 10% FBS. Human cancer cell
line A549 (lung carcinoma) from ATCC was maintained in
Dulbecco’s modified Eagle’s medium supplemented with
10% FBS.
Patient samples
PBMCs, CLL, lymphoma, multiple myeloma, and reac-
tive follicular hyperplasia cell samples were collected at the
Mayo Clinic from patients after informed consent and
Institutional Review Board approval had been obtained.
Mononuclear cells were isolated from postapheresis leu-
kocyte reduction chambers from healthy blood donors as
described (10). Monocyte populations were isolated using
CD14þ immunomagnetic bead selection followed by se-
quential isolation of CD3þ cells immunomagnetic selec-
tion for T cells (both from Miltenyi Biotec). Labeled cells
were separated on an AutoMACS separator (Miltenyi Bio-
tec) running the POSSEL program. Remaining cell popula-
tions after sequential isolation of monocyte and T cells
were lymphoid cells that are predominantly B cells. Typical
isolation purities for the positive selected cells are greater
than 95% (10). Patient cells were maintained in culture in
IMDM supplemented with 10% FBS.
Viruses
Ad4, Ad5, Ad6, Ad7, Ad11, Ad17, Ad24, Ad26, Ad28,
Ad30, Ad35, Ad45, and Ad48 were obtained from the
ATCC. Viruses were propagated in HEK 293 cells (also
from ATCC). Viruses were purified by CsCl purification
and quantitated by determining the optical density at
260 nm (OD260).
Analysis of in vitro infection and killing by Trypan
Blue uptake
Cell lines and/or patient cells were infected with
10,000 virus particles (vp) per cell for 1 hour at 4C.
Cells were then washed 3 times with Hank’s buffered
saline solution (HBSS, Invitrogen) and placed in a 37C
incubator for the indicated length of time. Loss of
membrane integrity was assessed by Trypan Blue uptake
as described by Barry and colleagues (1990). For neur-
aminidase-treated samples, cells were incubated with 5
mg/mL neuraminidase (SIGMA) at 4C for 1 hour prior
to incubation with virus.
Quantitative real-time PCR
Virally infected cells were harvested at the indicated time
points and DNA was isolated using DNeasy kit from
Qiagen. 100 ng of DNA was used in a real-time PCR assay
using SybrGreen reagent to quantitate viral genomes in
each sample. Samples were read using an ABI Prism
7900HT real-time instrument. A standard curve of the
corresponding viral plasmid DNA was used for quantita-
tion, using primers designed against hexon. Measurements
were made in triplicate.
Translational Relevance
This work analyzes the potential use of novel adeno-
virus serotypes as therapeutic agents against B-cell can-
cers. This work was done in part using primary patient
samples from myeloma and lymphoma patients to
ensure that the observations are relevant to clinical
translation. This work lays the foundation for generat-
ing conditionally replicating adenoviruses engineered
for selective systemic therapy against B-cell cancers in
human patients.
Mining the Adenovirus Virome
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Cell viability MTT assay
To assess blocking of viral binding, 4  104 Hep3B cells
were plated into each well of 96-well plates. Cells were then
incubated in HBSS containing 500 mL of 200 mg/mL lectin
from wheat germ agglutinin (SIGMA), 200 mg/mL man-
nose (SIGMA), or 22 mg/mL of cyclic 4-RGD peptide
(Invitrogen) for 1 hour at 4C. A total of 4  107 of the
indicated viral particles were then added to each well. After
7 days, cell viability was assessed by MTT assay (SIGMA).
n ¼ 3.
Blocking receptor binding
A total of 5 105 Hep3B cells were plated in each well of
24-well plates. An amount of 100 mL of 200 mg/mL lectin
from wheat germ agglutinin, 200 mg/mL mannose, or 22
mg/mL of cyclic 4-RGD peptide were added and incubated
with cells for 1 hour at 4C. A total of 5  108 particles of
Ad26 were added to each well and left to incubate for 1
hour at 37C. Wells were then washed 3 times with HBSS.
DNA was isolated from the cells using DNeasy from
Qiagen and quantitated by real-time quantitative PCR
(qPCR). n ¼ 3.
Ad26 CD46 receptor blocking
A total of 4  104 human reactive follicular hyperplasia
patient sample cells or Hep3B cells were plated into 96-well
plates. Cells were then incubated with 1.5 mg of IgG1
mouse isotype antibody (BD Pharmingen), mouse anti-
human CD46 from BD Pharmingen (anti-CD46a) or
mouse anti-human CD46 antibody from AbD Serotec
(CD46b) dialyzed in HBSS were added to each well. Plates
were then incubated at 4C for 1 hour. A total of 4 107 of
the indicated viral particles were then added to each well.
After 7 days, cell viability was assessed by MTT assay or
crystal violet staining. n ¼ 3.
Human lymphoma xenografts
A total of 3  106 RL (human lymphoma) cells were
injected subcutaneously into the hind flank of 4- to 6-
week-old nude mice (Harlan Sprague-Dawley). After pal-
pable tumors formed (14 days), the mice were injected
intratumorally with 3  1010 viral particles of wild-type
virus in 100 mL total volume of HBSS. Control groups
were injected with buffer alone. Tumors were observed
every other day and measured weekly. Volume was
calculated as 1/2 length  width  width. When animals
were found with tumor volumes exceeding 2,000 mL,
ulcerated tumors, or greater than 20% weight loss, they
were sacrificed. n ¼ 6.
Animals
All animal experiments were carried out according to the
provisions of the Animal Welfare Act, Public Health Service
Animal Welfare Policy, the principles of the NIH Guide for
the Care and Use of Laboratory Animals, and the policies
and procedures of Mayo Clinic. Female nude mice (4–6
weeks old) were purchased from Harlan.
Statistics
P values represent 2-tailed t test values unless otherwise
indicated. P < 0.05 considered significant.
Results
Infection and killing of PBMCs by adenoviruses
Adenoviruses from species B, C, and E have frequently
been identified in normal human PBMC and lymphoid
tissues (7). Our previous testing of adenoviruses from
species B, C, and D against bone marrow cells from
myeloma patients found that species D Ads 26 and 48
were most potent at killing myeloma cells while largely
sparing normal marrow cells (8). These data suggest that
different Ad serotypes from different virus species may have
unappreciated tropism for human hematologic cells.
To explore the ability of different Ads to infect and kill
normal cells, PBMCs from healthy volunteers were
enriched for CD14þ monocytes and CD3þ T cells by
positive selection. The remaining cell population after
sequential isolation of monocyte and T cells was predom-
inantly (95%) B cells (10). These cells were then incubated
with adenovirus representatives from different species. Ad
serotype 5 (Ad5) was tested as a benchmark oncolytic
because it is the only virus used to date in humans for
virotherapy. Other adenoviruses were chosen based on the
following criteria. First, their viral infection is well tolerated
by humans. Viruses associated with cancer (species A) or
obesity (species D Ad36) were excluded. Previously tested
species F gastrointestinal viruses Ad40 and Ad41 were
omitted as these were ineffective in all tests (Ref. 8; and
data not shown). Second, new viruses that were tested here
had to have low seroprevalence in humans to avoid neu-
tralization in patients if they were translated into the clinic.
Third, the viruses were genetically distinct and more likely
to possess novel phenotypes that might be more effective
against B-cell cancers.
Each cell population was incubated with each of the Ads
and cell viability was assessed by Trypan Blue exclusion
more than 7 days (Fig. 1). Addition ofmost of the viruses to





































Figure 1. Comparison of adenoviral serotypes for infection and killing of
normal PBMCs. The indicated cells were incubated for 7 days with the
indicated wild-type adenoviruses and cell viability was assessed by
Trypan Blue exclusion. MOI ¼ 10,000 viral particles/cell.
Chen et al.
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compared with controls. However, the untreated CD14þ
monocytes lost 50% viability, so toxicity by the viruses was
likely exaggerated by the nonoptimal culture conditions.
Treatment of CD3þ T cells withmost of the Ads caused little
loss of viability. The one exception was Ad11 that reduced
survival approximately 25%. Most of the viruses had little
effect on CD3/CD14 cells with the exception of Ad11
that reduced viability 30% (P¼ 0.0309). Ad26 also seemed
to have some toxicity to these cells; however, this did not
reach statistical significance. These data suggest that normal
T and B cells are relatively resistant to infection by most Ad
species, but that there is some evidence of cell killing by
select viruses. This is consistent with previous tests in
primary marrow cells (8). This is also consistent with
observations of persistent association of Ads with lympho-
cytes (11).
Oncolytic screen of Ad species on CLL and lymphoma
cell lines
Our previous data suggested that species D viruses were
most potent at killing primary patient myeloma cells while
largely sparing normal cells (8). Myeloma arises from
mature B-cell plasma cells, the last step of B-cell matura-
tion. Given their activity against these mature B-cell can-
cers, we tested select adenoviruses against B-cell cancers
arising from various stages of B-cell maturation. These
included CLL and B-cell lymphomas arising from various
stages of B-cell ontogeny.
Two viruses from each of species B, C, and D were first
tested on B-cell cancer cell lines representing cancers arising
at different stages of B-cell development: MEC1, MEC2,
Raji, and RL cells. MEC1 and MEC2 cells are human CLL
cell lines that express mature B-cell markers CD19, CD20,
CD21, and CD22. They are CD46 positive and coxsackie
and adenovirus receptor (CAR) negative. These 2 CLL cell
lines were derived from the same patient and differ mainly
in the expression of CD23 and FMC7 (9). RL cells are
human lymphoma cells that are EBV negative. RL cells are
derived from the ascites of a patient with diffuse large cell
lymphoma (12). Raji cells are an EBV-positive lymphoma
cell line derived from a patient with Burkitt’s Lymphoma
(13). Myeloma cell lines were tested previously (8).
Species B Ad11 and 35, species C Ad5 and 6, and species
D Ad26 and 48 were incubated with the indicated cell lines
and cell killing was monitored over time by loss of mem-
brane integrity assessed by Trypan Blue uptake (Fig. 2A–D).
Under these conditions, species B viruses were largely
ineffective against the CLL or lymphoma cell lines. Species
C Ad5 and Ad6 mediated intermediate killing over time on
all 4 cell lines, with Ad5 being slightly more effective than
Ad6. Consistent with results on myeloma, species D viruses
Ad26 and Ad48 were most effective in killing all of these B-
cell cancer cell lines with Ad26 generally being most
effective.
Replication of viruses in lymphoma cell lines
In most cases, oncolysis depends on the virus proceeding
through its life cycle. To test whether oncolysis of these cell
lines correlated with propagation of the virus life cycle,
adenoviral genome replication was assessed by real-time
qPCR at varied times after incubation with Epstein-Barr
Virus (EBV) positive Raji lymphoma cells and with EBV-
negative RL lymphoma cells. In addition to monitoring
viral genomes associated with the cells, qPCR after 1 hour
incubation at 4C with the cells also provides a relative
assessment of the number of virions that have successfully
bound to the cells.
qPCR testing of each of the viruses incubated for 1 hour
with Raji and RL cells revealed that the species B viruses
Ad11 and Ad35 bound most effectively (Fig. 2E and F).
Although these viruses were most effective at binding, they
failed to replicate their DNA. This is consistent with both
their inability to kill the cells and with previous observa-
tions on primary patient myeloma cells (8). In contrast, the
species C and D viruses bound to lower degrees, but
replicated their genomes and killed the cells. This higher
replication and killing of cells by species C and D viruses is
consistent with previous data in more mature myeloma
cancer cells (8).
Oncolytic testing on primary patient CLL and
lymphomas
While testing in cell lines provides useful guidance of
potential therapy, there is no substitute for testing in
primary patient cancers. To test this, CLL samples were
collected from 2 patients and these were incubated with
Ad5, 6, 11, 35, 26, and 48 (Fig. 3A and B). In this case, cell
killing was at most 50% greater by species D viruses than
the other viruses after 7 days. This is markedly weaker than
in immortalized CLL cell lines. Again, the species D viruses
Ad26 and Ad48 mediated the highest level of killing on
these B-cell cancers.
Patient samples from 2 grades of lymphoma were tested
with species B Ad7, Ad11 and Ad35, species C Ad5 and Ad6,
species D Ad26 and Ad48, and also with species E Ad4.
When tested on follicular lymphoma, the viruses only
mediated 35% cell killing within 7 days (Fig. 3C). Inter-
estingly, the viruses that utilize CAR (Ad4, 5, and 6) were
most potent against this particular type of solid tumor
lymphoma. In contrast, when tested against diffuse large
B lymphoma, many of the viruses had similar oncolytic
activity with the most potent virus being Ad26 (Fig. 3D).
Expanded screen of species D adenoviruses
These observations in CLL, lymphoma, and myeloma
indicated that the 2 species D viruses, Ad26 and Ad48, were
generally most effective against cancers spanning B-cell
development. This observation is interesting because these
viruses are largely unstudied despite constitutingmore than
half of the 55 human Ads.
On the basis of this, we hypothesized: (i) that species D
viruses might have a unique tropism for B-cell cancer cells;
(ii) that this tropism might make them particularly useful
as oncolytics in patients; and (iii) that species D viruses
might have differing abilities to kill B-cell cancers from
different steps of B-cell ontogeny.
Mining the Adenovirus Virome
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To test these hypotheses, a broader set of species D
viruses including Ads 17, 24, 26, 28, 30, 45, and 48 were
compared with species B Ads 7, 11, and 35, species C Ads 5
and 6, and species E Ad4. In agreement with results
obtained using the smaller panel of viruses (Fig. 2), all
species D viruses were superior to species B, C, and E viruses
for killing the RL EBV-negative lymphoma cells (Fig. 4A).
Species C and E viruses mediated intermediate levels of cell
killing. Species B viruses again showed no significant killing
effect.
When the 13 virus serotype panel of viruses was tested
against primary marginal zone lymphoma cells from a
patient, these cells were efficiently killed by all of the
species D viruses. No other viruses were effective against
these cells.
The 13 virus serotype panel was also tested on cells from
a multiple myeloma patient. Testing on bone marrow
samples from myeloma afforded the opportunity to com-
pare viral cell killing on normal cells versus cancer cells
because these cells can be separated by purification on
CD138 antibody beads. When the 13 virus panel was tested
on CD138-negative (Fig. 4C) and CD138-positive marrow
cells, the species D viruses were the most effective at killing
the CD138þmalignant cells (Fig. 4D). In contrast, marked-
ly lower cell killing was observed in CD138-noncancerous
cells.
Due to the limited availability of patient sample cells and
the large number of viruses being screened in the Trypan
Blue viability assays, Figs. 2–4 were each tested with only 1
sample. To compare the oncolytic activity of the viruses
against the highly proliferative patient B-cell cancers sta-
tistically, data from the marginal zone lymphoma patient
was pooled with that frommultiplemyeloma patients from
Figs. 4 and 7 as well as 2 additional multiple myeloma
patient samples not included within the figures presented
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Figure 2. Comparison of
adenoviral serotypes for infection
and replication in B-cell cancer
cell lines. Comparison of cell
killing of either MEC1 (A) or MEC2
(B) CLL cell lines by adenoviruses
as assessed by Trypan Blue
uptake following infection with
virus at an MOI of 10,000 viral
particles/cell. Killing of either Raji
(C) or RL (D) human lymphoma cell
lines by adenoviruses as assessed
by Trypan Blue uptake. E and F,
real-time qPCR showing viral
genome copies present within
cells more than 1-week time
course following infection for cells
in C and D. n ¼ 3.
Chen et al.
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consistent effect on the 5 patient samples, all of the species
D viruses showed significant cell killing (Ad17, P¼ 0.0031;
Ad24, P ¼ 0.0002; Ad26, P < 0.0001; Ad28, P < 0.0001;
Ad30, P ¼ 0.0004; Ad45, P < 0.0001; Ad48, P ¼ 0.0003).
Given the inherent heterogeneity between these patient
samples, the higher activities of the species D viruses seem
significant.
In vivo testing of Ads in mouse xenografts of human
lymphoma
To evaluate whether in vitro studies could be relevant to
in vivo therapy, RL lymphoma tumors were initiated by
subcutaneous injection of the cells into the flanks of nude
mice. Once tumors reached volumes of 200 mm3, groups
of 6 mice were injected intratumorally a single time with 3
 1010 vp of selected viruses. Because species D Ad26 and
Ad45 were generally the most potent of the 13 tested Ads,
these 2 viruses were tested. For comparison, another group
ofmice were injected with the same dose of Ad5 (species C)
that was less effective in vitro. A final group was injected
with buffer alone. Tumor volume was measured weekly
(Fig. 6). Under these conditions, both Ad26 and Ad45
mediated significant delay in tumor growth after only a
single injection. In contrast, both buffer-treated and Ad5-
treated tumors grew unchecked requiring animals to be
sacrificed within 2 weeks.
Receptor utilization by species D adenoviruses
These data indicate that species D viruses have unique
efficacy against B-cell cancers spanning the ontogeny of
normal B cells. One of the main differences between the
different subgroups of adenovirus is their receptor speci-
ficity. Species C and E Ads are known to bind cellular CAR
with high affinity and utilize their fiber proteins to then
bind and enter cells via interactions of penton base with av
integrins (14, 15). In contrast, species B viruses bind CD46
and perhaps other receptors with their fibers (16–18).
Despite the fact that species D Ads represent more than
half of all human adenoviruses, these viruses are diverse
and relatively unstudied. Species D viruses can bind CAR,
CD46, and sialic acid with their fiber proteins (Refs. 19–23
and Supplementary Fig. S1). Although they can bind all of
these receptors, species D Ads have short fibers with only 8
repeats making them unable to efficiently enter cells using
CAR (21). When Ad26 and 48 were vectored as replication-
defective vaccines, receptor utilization studies suggested
that they did not use CAR and only weakly used CD46
as a receptor (24). Sialic acid binding was not tested. From
this, it is unclear whether all species D viruses use the same
receptors and if receptor specificity of these viruses explains
their unique ability to kill B-cell cancers.
These data suggested that the subgroup D viruses might
use sialic acid, CAR, or CD46 for binding and killing B-cell
Figure 3. Comparison of
adenoviral serotypes for infection
and replication of primary B-cell
cancer cells. A and B, 1 week cell
viability of 2 different CLL patient's
sample cells after infection with 6
different adenoviral serotypes. C,
viability of follicular grade 2 cancer
lymphoma patient sample cells
following infection by a panel of 8
adenoviral serotypes. D, viability
of diffuse large B-cell lymphoma
patient sample cells following
infection by panel of 8 adenoviral
serotypes. Experiments were
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cancers. An alternate possibility is that the viruses may be
binding to av integrins with RGD motifs on penton base
(19). To test these possibilities, virus infection was assessed
with and without incubation with agents that could block
interactions with these receptors (Fig. 7). Because a sialic
acid binding motif of fiber is well conserved on these
species D viruses (Supplementary Fig. S1), they were tested
for their ability to bind sialic acid by treating primary
CD138þ myeloma cells with neuraminidase to remove
cell surface sialic acid residues prior to incubation with the
viruses (Fig. 7A). Under these conditions, no obvious
effects of removal of sialic acid were observed. To test
the role of integrin binding by RGD motifs on the viruses,
Hep3B cells were incubated with the cyclic RGD-4C pep-
tide (25) prior to virus exposure and cell viability was
measured 7 days later (Fig. 7B). In contrast to the weak
effects of neuraminidase, the RGD-4C peptide partially
inhibited oncolysis by species D viruses Ad17, 24, 26,
and 48 (P ¼ 0.0076, P ¼ 0.0019, P ¼ 0.0011, and P ¼
0.0091, respectively), but not cell killing by species D
viruses Ad28, 30, or 45 (P ¼ 0.8717, P ¼ 0.8914, and P
¼ 0.0609, respectively). To test this further, Hep3B cells
were incubated with wheat germ agglutinin (WGA) to
block cell surface sialic acids or with cyclic RGD before
addition of the potent Ad26 virus (Fig. 7C). qPCR for viral
genomes showed no reduction in virus binding byWGA. In
contrast, cRGD inhibited Ad26 binding more than 50% (P
¼ 0.034). To test whether CD46 binding was involved in
virus killing, primary patient reactive follicular hyperplasia
cells were incubated with a blocking CD46 antibody or
with isotype control antibody before the addition of species
B Ad7, species C Ad5, and species D Ad26. Consistent with
previous results, Ad26 mediated more cell killing than Ad5
or Ad7. Incubation with the CD46 antibody reduced cell
killing nearly 50% (P ¼ 0.067). Combination of CD46
antibody and cyclic-RGD peptide on patient myeloma cells
mediated complete protection against killing by Ad26,
suggesting that both receptors are being utilized by the
virus (Supplementary Fig. S2).
Discussion
Following the first government approval for the use of
oncolytic adenovirus in the treatment of head and neck
cancers, researchers have been exploring the use of repli-
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Figure 4. Expanded comparison of adenoviral serotypes for infection and replication in B-cell cancer cells. A 13-member panel of adenoviral serotypes
are tested against 2 B-cell cancers. Lymphoma: A, RL human lymphoma; B, patient marginal zone lymphoma. Myeloma: C, nonmalignant CD138 patient
bone marrow cells; D, malignant C138þ patient bone marrow cells. Viability was assessed by Trypan Blue uptake following infection at an MOI of
10,000 viral particles/cell. Green, species B; blue, species C; yellow, orange, red, species D; and brown, species E.
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Ad5 is the most common vector being studied for this
purpose. However, 27% to 100% of people in populations
throughout the world are predicted to have neutralizing
antibodies against Ad5 viral proteins (24, 27). The pre-
sumed neutralization of the therapeutic vector in a large
group of individuals makes Ad5 a poor choice for an
oncolytic in these patients. More recent studies have
probed alternative less prevalent adenoviruses for efficacy
against cancer cells (8, 28–32). In a recent study against
myeloma, Ad5 and Ad6 species C viruses showedmoderate
anticancer effect against cell lines and primary multiple
myeloma patient cells. However, Ad26 and Ad48 species D
viruses were more proliferative in these cells (8). This is
surprising considering species D viruses do not infect
human solid tumor cancer cell lines (33). On the basis
of these data, we hypothesized that uncommon species D
viruses are superior to Ad5 for the treatment of B-cell
cancers.
To test this hypothesis, species B, C, and D adenoviruses
were tested against B lineage cancer cell lines and primary
patient samples. As predicted by our previous myeloma
study, Ad26 and Ad48 and all tested species D viruses were
effective against all of the cell lines. When the viruses were
tested against primary patient CLL, myeloma, and lympho-
ma samples, the species D viruses were againmost effective,
but were not as active against CLL as against lymphoma
and myeloma cells. Given that immortalized cell lines
acquire additional modifications, it is not entirely surpris-
ing that a dichotomy in responses was observed between
CLL cell lines and primary samples. Fortunately, the species
D viruses remained active against most of the primary
lymphoma samples and against all tested myeloma cancer
cells. In future studies, it may be interesting to further
characterize cells that are refractory to cell killing. For
example, it would be useful to determine the precise
changes in cellular receptor expression that occur as pri-
mary cells are converted to immortalized cell lines. In
primary patient sample cells, refractory populations are
likely nonmalignant. Better sorting methods may reduce
the number of these cells within samples.
These data suggest that species D adenoviruses are most
effective against lymphomas and myelomas-–the B-cell
cancers arising from the later stages of B-cell ontogeny.
To some degree, there seems to be correlation between the
ability of the viruses to kill B-cell cancers and their prolif-
erative capacity. This is particularly notable in the ability of
the viruses to kill immortalized CLL cell lines, but to have
markedly less effect on primary CLL samples and slower
growing lymphomas.
Slow growing B-cell lymphomas and leukemias include:
follicular lymphoma (the most common slow-growing
NHL), CLL (also known as SLL), lymphoplasmacytic lym-
phoma, marginal zone lymphoma, mucosa-associated
lymphoid tissue (MALT) lymphoma, and Waldenstr€om
macroglobulinemia. Fast growing NHLs include diffuse
large B-cell lymphoma (the most common fast-growing
NHL), AIDS-associated lymphoma, anaplastic large–cell
lymphoma, Burkitt lymphoma, central nervous system
lymphoma, lymphoblastic lymphoma, MALT lymphoma,
mantle cell lymphoma, and peripheral T-cell lymphoma.
The CLL samples, and 2 of the 3 lymphoma samples
obtained for this study were follicular grade 2 lymphoma
and marginal zone lymphoma in the slow growing lym-
phoma group. The third lymphoma sample was a diffuse
large lymphoma in the fast-growing group. Although the
species D adenoviruses killed all of these cancers, there was
no clear correlation between general cancer growth phe-
notype and oncolytic susceptibility. This could reflect the
artificial in vitro testing that does not necessarily recapitu-
late the growth patterns of these cells in vivo. Future clinical
testing will be needed to determine whether an association
with growth and oncolysis exists.
Because species D viruses were selective against lympho-
ma cell lines and patient cells, the 2 best conducting species
D viruses Ad26 and Ad45 were compared with Ad5 for in
vivo efficacy against RL tumor xenografts. In this case, a
single intratumoral injection of 3  1010 viral particles
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Figure 5. Pooled cell viability data from 5 patient B-cell cancers. The
marginal zone lymphoma patient sample data was pooled with cell killing
data of 4 patients' multiple myeloma samples. Individual viabilities (y-axis)
from each experiment are presented as points above the viral serotype




























Figure 6. In vivo comparison of select adenoviral serotypes for killing of
lymphoma xenografts in nude mice. RL lymphoma tumors were initiated
subcutaneously in nude mice. Groups of 6 tumor-bearing mice were
injected intratumorally a single time with 3  1010 vp of the indicated
adenoviruses. Tumor size was monitored over time after injection and
mean tumor sizes are shown. Lines end when the first animal of the group
had to be sacrificed to avoid misleading skewing of the lines as larger
tumors are removed.
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of these animals. Ad5 was ineffective against these tumors.
Although single intratumoral injection of species D ade-
noviruses was unable to completely kill tumors, future
studies using sequential treatment injections are likely to
show additional therapeutic benefit. It will be interesting to
assess the response of regressive tumors to these secondary
treatments. If tumor cells that are resistant to infection and
killing by one species D serotype persist and clonally
expand, a serotype switch approach may show the greatest
antitumor effect.
These data suggest that subgroup D viruses may have
utility as oncolytics against myeloma and lymphoma.
Moreover, species D viruses are the only fully replication
competent adenoviruses to show efficacy against lympho-
ma. It should be noted that a conditionally replicating Ad5
carrying the melanoma differentiation-associated gene-7/
interleukin-24 transgene was effective against a rare CAR
expressing lymphoma (34). Subgroup C viruses also seem
effective against myeloma; however, because of the sero-
prevalence of Ad5, either a subgroup D virus or Ad6 would
seem a better choice of vector for future studies.
The work presented herein begs the question, what
cellular factors expressed by B-cells and what viral factors
related to species D viruses make species D viruses more
oncolytic against B-cell cancers? Our data suggest that these
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Figure 7. Receptor blocking
during species D adenovirus
infection. A, 13-panel adenoviral
infection (MOI ¼ 1,000 viral
particles/cell) of patient CD138þ
multiple myeloma cells with (right)
and without (left) prior treatment
with neuraminidase to remove
sialic acid. B, viability of Hep3B
cells 1 week following infection by
the 13 adenoviruses (x-axis) in the
presence or absence of cyclic
RGD peptide. 0, uninfected.
P value of 2-tailed t test. C, effects
of WGA or cyclic RGD on Ad26
binding to Hep3B cells as
assessed by qPCR. 0, uninfected.
P value of 1-tailed t test. D,
blocking CD46 binding of Ad26 to
human patient reactive follicular
hyperplasia cells by addition of
isotype or anti-CD46 antibody.
*, P < 0.05. **, P < 0.01.
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combination of CD46 and integrin as receptors. Neither
CD46 nor integrin blockade completely inhibited species
D virus cell killing. Therefore, the viruses may use both
receptors in combination as suggested by the data from
Supplementary Fig. S2 or may utilize an as yet uncharac-
terized receptor for infection of these B cells.
Testing of viruses from species B, C, D, and E on normal
PBMCs and on bone marrow cells here and previously
(34) suggest that these noncancerous cells are relatively
resistant to lethal infection by the viruses. Previous anal-
ysis of viral binding and replication in marrow samples
from myeloma patients indicated that species B Ad11
binds both "normal" CD138 marrow cells and cancer-
ous CD138þ myeloma cells 100-fold more strongly than
species C or D viruses. This is interesting given that Ad11
was almost always the only virus that showed any cyto-
toxicity against normal T and B cells. Although Ad11
binds marrow cells well, it does not seem to replicate
indicating that at least in marrow, this is not a productive
infection. Whether it or other Ad serotypes from the
diverse species tested here bind and undergo abortive
or productive infections in PBMCs remains to be tested.
Although most of the viruses spared normal cells from
killing, safe clinical translation into patients will likely
require that these species D viruses be engineered condi-
tionally replicating adenoviruses (CRAd) for these B-cell
cancers. This may be achieved by mutation of E1A or B
interactions with tumor suppressors or by putting early
genes under control of cancer or cell-specific promoters
(reviewed in ref. 3).
In summary, adenoviruses seem to interact with normal
and cancerous hematologic cells. These observations have
implications for interactions of these viruses with normal
blood cells and for their use as oncolytic agents. In this
regard, species D adenoviruses seem most robust at killing
B-cell cancers arising from later steps in B-cell ontogeny.
The specificity of this oncolytic phenotype is not precisely
known but is likely due to a combination of viral fiber
length and available cellular receptors. Conversion of these
wild-type viruses to CRAds for cancer-specific or B cell-
specific replication will likely be important next steps to
maximize their efficacy and safety for clinical translation
into humans.
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 1
Supplemental Figure 1.  Alignment of the Knob Domains of Fibers.  The cell 
binding knob domains of the tested species D adenoviruses were aligned to 
benchmark Ads known to bind CAR (Ad5), CD46 (Ad11), and sialic acid (Ad37).  
Conserved amino acids involved in binding these receptors are indicated by 
circles (CAR), diamonds (CD46), or triangles (sialic acid) above the sequence.  
Solid symbols indicate near complete conservation of the given residue.  Open 
symbols indicate partial conservation.  Diamonds, circles, and triangles to the 
right of the alignments indicate the number of conserved residues for that line 
that are present in each of the species D knobs as an approximation if the virus 
could utilize the receptor.  Presence of many of the conserved residues would 
support possible use of the receptor for binding (but not necessarily infection).   
Supplemental Figure 2.  Blocking of both CD46 and RGD interactions with 
Ad26.  CD138+ multiple myeloma primary patient cells were incubated with Ad26 
virus with or without CD46 blocking antibody and cyclic-RGD peptide.  MOI = 
1,000.  Viability of cells was measured by MTT assay seven days post-infection. 
 


